Analysis of Liver Dysfunction After Day 100 in 40 Evaluable Patients According to HCV and HGV Virus Status
| . | None . | HGV RNA+ . | HCV RNA+ . | HCV RNA and HGV RNA+ . |
|---|---|---|---|---|
| . | (n = 20) . | (n = 13) . | (n = 4) . | (n = 3) . |
| Median follow-up (d) | 532 (278-929) | 536 (347-992) | 662 (552-823) | 460 (283-921) |
| Underlying disease | ||||
| CML | 11 | AL 11 | AL 3 | AL 2 |
| AL | 5 | SAA 1 | CML 1 | CML 1 |
| MDS | 2 | CML 1 | ||
| SAA | 2 | |||
| Liver dysfunction | 10/20 | 8/13 | 3/4 | 3/3 |
| Type of liver dysfunction | ||||
| Chronic GVHD | 6 | 4 | 1 | |
| Iron overload | 3 | 2 | 1 | 1 |
| CAH | 1 | |||
| Acute viral hepatitis | 1 | |||
| Steatohepatitis | 1 | |||
| Undetermined | 1 | 1 | 1 | |
| ALT levels at last clinical visit | ||||
| (Normal/abnormal | 16/4 | 11/2 | 1/3 | 0/3 |
| % patients with abnormal levels) | 20% | 15% | 75% | 100% |
| . | None . | HGV RNA+ . | HCV RNA+ . | HCV RNA and HGV RNA+ . |
|---|---|---|---|---|
| . | (n = 20) . | (n = 13) . | (n = 4) . | (n = 3) . |
| Median follow-up (d) | 532 (278-929) | 536 (347-992) | 662 (552-823) | 460 (283-921) |
| Underlying disease | ||||
| CML | 11 | AL 11 | AL 3 | AL 2 |
| AL | 5 | SAA 1 | CML 1 | CML 1 |
| MDS | 2 | CML 1 | ||
| SAA | 2 | |||
| Liver dysfunction | 10/20 | 8/13 | 3/4 | 3/3 |
| Type of liver dysfunction | ||||
| Chronic GVHD | 6 | 4 | 1 | |
| Iron overload | 3 | 2 | 1 | 1 |
| CAH | 1 | |||
| Acute viral hepatitis | 1 | |||
| Steatohepatitis | 1 | |||
| Undetermined | 1 | 1 | 1 | |
| ALT levels at last clinical visit | ||||
| (Normal/abnormal | 16/4 | 11/2 | 1/3 | 0/3 |
| % patients with abnormal levels) | 20% | 15% | 75% | 100% |
Abbreviation: CAH, chronic active hepatitis.